Pacira BioSciences, Inc.
PCRXNASDAQHealthcare● Active
$22.86
+$0.11(+0.48%)
Market Cap$899198100
P/E Ratio—
52W High$27.64
52W Low$18.8
Pacira BioSciences, Inc. (PCRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PCRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$0.60
Est. $0.61 · -1.6%
Revenue
$0.18B
Est. $0.17B · +3.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
PCRX reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.64 | — | — | — | $0.19B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | $0.61 | $0.60 | -1.6% | $0.18B | $0.17B | +3.3% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $0.85 | $0.57 | -32.9% | $0.20B | $0.20B | -1.7% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.65 | $0.70 | +7.7% | $0.18B | $0.20B | -11.1% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.72 | $0.74 | +2.8% | $0.18B | $0.18B | -0.7% |
| ▲ Q2 FY2025 | May 8, 2025 | $0.57 | $0.62 | +8.8% | $0.17B | $0.19B | -9.9% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $0.78 | $0.91 | +16.7% | $0.19B | $0.19B | +1.0% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.72 | $0.79 | +9.7% | $0.17B | $0.18B | -6.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.64
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
$0.60
EPS Est.
$0.61
EPS Surpr.
-1.6%
Revenue
$0.18B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
$0.57
EPS Est.
$0.85
EPS Surpr.
-32.9%
Revenue
$0.20B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.70
EPS Est.
$0.65
EPS Surpr.
+7.7%
Revenue
$0.18B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.74
EPS Est.
$0.72
EPS Surpr.
+2.8%
Revenue
$0.18B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.62
EPS Est.
$0.57
EPS Surpr.
+8.8%
Revenue
$0.17B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.91
EPS Est.
$0.78
EPS Surpr.
+16.7%
Revenue
$0.19B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.79
EPS Est.
$0.72
EPS Surpr.
+9.7%
Revenue
$0.17B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.97 | $0.98 | $0.99 | 2 |
| Q3 FY2027 | $0.87 | $0.88 | $0.89 | 1 |
| Q2 FY2027 | $0.84 | $0.85 | $0.86 | 1 |
| Q1 FY2027 | $0.75 | $0.76 | $0.77 | 2 |
| Q4 FY2026 | $0.85 | $0.86 | $0.87 | 2 |
| Q3 FY2026 | $0.70 | $0.77 | $0.83 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -1.6% | $25.14 | $25.49 | +1.39% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -32.9% | $23.46 | $22.59 | -3.71% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +7.7% | $21.85 | $21.10 | -3.43% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +2.8% | $22.94 | $22.54 | -1.74% |
| ▲ Q2 FY2025 | May 8, 2025 | +8.8% | $25.18 | $24.91 | -1.07% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +16.7% | $25.48 | $25.38 | -0.39% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +9.7% | $17.28 | $17.67 | +2.26% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +21.9% | $20.36 | $19.54 | -4.03% |
Q2 FY2026+1.39%
Report Date
Apr 30, 2026
EPS Beat/Miss
-1.6%
Price Before
$25.14
Price After
$25.49
Q1 FY2026-3.71%
Report Date
Feb 26, 2026
EPS Beat/Miss
-32.9%
Price Before
$23.46
Price After
$22.59
Q4 FY2025-3.43%
Report Date
Nov 6, 2025
EPS Beat/Miss
+7.7%
Price Before
$21.85
Price After
$21.10
Q3 FY2025-1.74%
Report Date
Aug 5, 2025
EPS Beat/Miss
+2.8%
Price Before
$22.94
Price After
$22.54
Q2 FY2025-1.07%
Report Date
May 8, 2025
EPS Beat/Miss
+8.8%
Price Before
$25.18
Price After
$24.91
Q1 FY2025-0.39%
Report Date
Feb 27, 2025
EPS Beat/Miss
+16.7%
Price Before
$25.48
Price After
$25.38
Q4 FY2024+2.26%
Report Date
Nov 6, 2024
EPS Beat/Miss
+9.7%
Price Before
$17.28
Price After
$17.67
Q3 FY2024-4.03%
Report Date
Jul 30, 2024
EPS Beat/Miss
+21.9%
Price Before
$20.36
Price After
$19.54
Avg Beat Reaction-1.40%
Avg Miss Reaction-1.16%
Beat Rate6 / 8 quarters
Largest Move-4.03% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PCRX ends December
Pacira BioSciences, Inc. (PCRX) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $0.60 — missing the analyst consensus of $0.61 by -1.6%. The next PCRX earnings date is expected around September 1, 2026.
Each quarter, investors track PCRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PCRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PCRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PCRX earnings · 5 questionsPacira BioSciences, Inc.'s next earnings report is expected around September 1, 2026. PCRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PCRX historically reports after market close (AMC).
PCRX earnings datewhen is PCRX earningsPCRX next earnings datewhen does PCRX report earningsPCRX earnings calendar
▸ Source: FMP · Pacira BioSciences, Inc. SEC filings · US GAAP · Pacira BioSciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026